Skip to main content
SHANGHAI SERUM BIO-TECHNOLOGY CO., LTD. logo

SHANGHAI SERUM BIO-TECHNOLOGY CO., LTD. — Investor Relations & Filings

Ticker · 688163 ISIN · CNE1000059X8 LEI · 8368001TREMN2G5DDS70 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 335 across all filing types
Latest filing 2023-04-20 Board/Management Inform…
Country CN China
Listing Shanghai Stock Exchange 688163

About SHANGHAI SERUM BIO-TECHNOLOGY CO., LTD.

https://www.serum-china.com.cn/en/

Shanghai Serum Bio-Technology Co., Ltd. is a specialized biopharmaceutical enterprise focused on the research, development, and manufacturing of therapeutic biological products. The company primarily produces a range of antiserums and antitoxins, including specialized antivenoms for various snake species, tetanus antitoxins, and rabies immunoglobulins. Its product portfolio supports emergency medical care and infectious disease management. The organization maintains advanced production facilities compliant with Good Manufacturing Practice (GMP) standards to ensure the safety and efficacy of its biological treatments. By leveraging biotechnological innovation, the company serves clinical needs in healthcare sectors, providing critical life-saving interventions for envenomation and acute bacterial toxins.

Recent filings

Filing Released Lang Actions
赛伦生物：第三届董事会第十二次会议决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of resolutions passed at a board of directors meeting of Shanghai SAILUN Biotechnology Co., Ltd. It details the meeting date, attendance, voting results, and the agenda items approved, including approval of the 2022 annual board work report, financial statements, profit distribution plan, annual report, and other corporate governance matters. The document repeatedly states that these items will be submitted to the 2022 annual shareholders meeting for approval. It also references other announcements and reports published separately on the Shanghai Stock Exchange website. The document is not the annual report itself, nor does it contain detailed financial statements or management discussion and analysis. It is a board meeting resolution announcement, which fits the category of Board/Management Information (MANG). The document length is short (1900 characters), and it is not a report publication announcement or regulatory filing. Therefore, the best classification is MANG with high confidence.
2023-04-20 Chinese
方正证券承销保荐有限责任公司关于上海赛伦生物技术股份有限公司2022年度募集资金存放与使用情况的专项核查意见
Audit Report / Information Classification · 95% confidence The document is a detailed special audit opinion report on the storage and use of funds raised by Shanghai Sailun Biotechnology Co., Ltd. in 2022. It includes specific financial figures about the amount raised, usage, balance, and management of the raised funds, as well as compliance with regulatory requirements. The document references regulatory rules related to fundraising and fund management, and it is issued by the underwriting and sponsoring institution. It is not a general annual report or earnings release but a specialized audit and compliance report focused on the use of raised capital. This fits the definition of an Audit Report / Information (AR), which includes standalone audit reports and applied accounting principles related to specific financial activities, excluding full annual reports. The document length and content confirm it is the report itself, not just an announcement or certification. Therefore, the correct classification is AR with high confidence. FY 2022
2023-04-20 Chinese
赛伦生物：2022年年度报告摘要
Annual Report Classification · 100% confidence The document is titled as the "2022 年年度报告摘要" which translates to "2022 Annual Report Summary". It contains detailed company information including business overview, industry analysis, product descriptions, financial data for multiple years and quarters, shareholder information, and risk disclosures. The length is over 13,000 characters, indicating a comprehensive report rather than a brief announcement. The content includes audited financial figures, management discussion, and analysis of business and industry conditions, which are typical components of an Annual Report. There is no indication that this is merely an announcement or a certification. Therefore, this document fits the definition of an Annual Report (10-K). FY 2022
2023-04-20 Chinese
赛伦生物：2023年第一季度报告
Interim / Quarterly Report Classification · 100% confidence The document is titled '2023 年第一季度报告' which translates to '2023 First Quarter Report'. It contains detailed financial data including consolidated and parent company balance sheets, profit and loss statements, cash flow statements, and notes on financial performance for the first quarter of 2023. The report explicitly states it is unaudited and covers the period January to March 2023. The presence of comprehensive financial statements and analysis for a period shorter than a full fiscal year clearly identifies this as an Interim / Quarterly Report. The document length is substantial (15,000 characters), and it contains actual financial data, not just an announcement or certification. Therefore, the correct classification is 'IR' (Interim / Quarterly Report). Q1 2023
2023-04-20 Chinese
赛伦生物：关于监事辞职及补选监事的公告
Board/Management Information Classification · 100% confidence The document is an announcement regarding the resignation of a supervisory board member and the nomination of a new candidate for the supervisory board. It includes details about the resignation, the legal implications, and the nomination process, along with the nominee's resume. There are no financial statements, earnings data, or detailed financial analysis present. The document is a formal announcement about changes in the company's supervisory board, which falls under management or board changes. Therefore, the appropriate classification is 'Board/Management Information (MANG)'. The document length is short and it is not a report or a certification, so it is not a regulatory filing or report publication announcement.
2023-04-20 Chinese
赛伦生物：关于使用部分超募资金永久补充流动资金的公告
Capital/Financing Update Classification · 95% confidence The document is an official announcement by Shanghai SAILUN Biotech Co., Ltd. regarding the use of a portion of over-raised funds to permanently supplement working capital. It details the board and supervisory committee meetings, independent directors' opinions, and the need for shareholder approval. The document references regulatory guidelines and approvals but does not contain financial statements or detailed financial performance data. It is a formal disclosure about capital use and funding allocation, not a full financial report or earnings release. The document length is 3322 characters, which is relatively short and focused on a specific capital use announcement. Therefore, it fits best under Capital/Financing Update (CAP).
2023-04-20 Chinese

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.